Min Lin

Min Lin is an experienced executive in biologics and CMC, currently serving as the Executive Director of Biologics CMC at Aditum Bio since September 2025. Prior to this role, Min Lin held the position of Executive Director CMC at WuXi Biologics and served as Executive Director of Biologics Development & Manufacturing at Chinook Therapeutics, Inc. Between 2019 and 2022, Min Lin was the Senior Director of Process Development at Sangamo Therapeutics, Inc., and previously held senior and director-level roles at Ultragenyx, Boehringer Ingelheim, and Bayer. Min Lin began a professional career as a Postdoc Fellow at Stanford Health Care after earning a PhD in Nutrition from the University of California, Berkeley, and holds a BS in Biochemistry from Fudan University.